NeoGenomics Inc (STU:NG9)
€ 12.6 -0.1 (-0.79%) Market Cap: 1.76 Bil Enterprise Value: 1.96 Bil PE Ratio: 0 PB Ratio: 1.97 GF Score: 76/100

Neogenomics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 10:20PM GMT
Release Date Price: €43.4 (+2.36%)
Casey Rene Woodring
JPMorgan Chase & Co, Research Division - Research Analyst

My name is Casey Woodring. I'm a member of the life sciences tools and diagnostics research team at JPMorgan. Today, It's my pleasure to introduce the management team from NeoGenomics. (Operator Instructions)

And with that, let me turn it over to Doug. Doug?

Douglas M. VanOort
NeoGenomics, Inc. - Chairman & CEO

Okay. Thank you, Casey, and thanks for inviting us to the conference this year. We're really pleased to be able to share the NeoGenomics story. And we think it's a story that's getting better and better, and we have enormous potential for the future.

Now for those of you looking at the presentation, I think we can bring up the slide deck. Let's turn to Slide 3, and we'll give you a quick sense for who we are. We're a comprehensive oncology diagnostics company, and we really exist because cancer patients need help with precision therapies. And we're in the business of precision medicine, and that's what we do. Our emphasis and our employees are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot